Presentation is loading. Please wait.

Presentation is loading. Please wait.

Hyperinsulinemic-euglycemic clamp–derived insulin sensitivity (glucose disposal), model-derived insulin secretion parameters (sensitivity first-phase insulin.

Published byStefanie Müller Modified over 5 years ago

Similar presentations

Presentation on theme: "Hyperinsulinemic-euglycemic clamp–derived insulin sensitivity (glucose disposal), model-derived insulin secretion parameters (sensitivity first-phase insulin."— Presentation transcript:

1 Hyperinsulinemic-euglycemic clamp–derived insulin sensitivity (glucose disposal), model-derived insulin secretion parameters (sensitivity first-phase insulin secretion and sensitivity second-phase insulin secretion), and CDI (glucose disposal · sensitivity first-phase insulin secretion) among the three groups of NGT and the IGT youth. *ANCOVA test. Hyperinsulinemic-euglycemic clamp–derived insulin sensitivity (glucose disposal), model-derived insulin secretion parameters (sensitivity first-phase insulin secretion and sensitivity second-phase insulin secretion), and CDI (glucose disposal · sensitivity first-phase insulin secretion) among the three groups of NGT and the IGT youth. *ANCOVA test. Cosimo Giannini et al. Diabetes 2012;61: ©2012 by American Diabetes Association

Download ppt "Hyperinsulinemic-euglycemic clamp–derived insulin sensitivity (glucose disposal), model-derived insulin secretion parameters (sensitivity first-phase insulin."

Similar presentations

Journal Club 埼玉医科大学 総合医療センター 内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University 松田 昌文 Matsuda, Masafumi.

Journal Club 埼玉医科大学 総合医療センター 内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University 松田 昌文 Matsuda, Masafumi.
Stages in the development of type 2 DM from a pre-diabetic, insulin-resistant state. As insulin sensitivity decreases, insulin-mediated glucose disposal.

Stages in the development of type 2 DM from a pre-diabetic, insulin-resistant state. As insulin sensitivity decreases, insulin-mediated glucose disposal.
Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.
Choosing a test of glucose metabolism in mice.

Choosing a test of glucose metabolism in mice.
Glucose homeostasis: roles of insulin and glucagon. 1A.

Glucose homeostasis: roles of insulin and glucagon. 1A.
Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Insulin and glucagon secretion: nondiabetic and diabetic subjects.
Postprandial glucose flux in nondiabetic controls.

Postprandial glucose flux in nondiabetic controls.
Prediabetes in youths: mechanisms and biomarkers

Prediabetes in youths: mechanisms and biomarkers
Box plot representing the median GIRs (mg/kg/min) by CD300LG genotype during the last 30 min of the HEC. The center lines show the medians; box limits.

Box plot representing the median GIRs (mg/kg/min) by CD300LG genotype during the last 30 min of the HEC. The center lines show the medians; box limits.
Fasting plasma adiponectin concentration in relation to body mass index (BMI) (A), waist circumference (B), acute insulin response (AIR) (C) and insulin.

Fasting plasma adiponectin concentration in relation to body mass index (BMI) (A), waist circumference (B), acute insulin response (AIR) (C) and insulin.
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
Comparison of triglycerides AUC 480’ between IGT+reduced FPIS group, IGT+preserved FPIS group, and IGT+reduced FPIS+reduced FPIS and FPIS restitution with.

Comparison of triglycerides AUC 480’ between IGT+reduced FPIS group, IGT+preserved FPIS group, and IGT+reduced FPIS+reduced FPIS and FPIS restitution with.
(A–B) Differences in fat oxidation during the hyperinsulinemic euglycemic clamp between African–American and non-Hispanic white women after 7 days of a.

(A–B) Differences in fat oxidation during the hyperinsulinemic euglycemic clamp between African–American and non-Hispanic white women after 7 days of a.
Hyperinsulinemic-euglycemic clamps revealed that obese TPL2KO mice have an improved insulin sensitivity compared with obese WT mice. Hyperinsulinemic-euglycemic.

Hyperinsulinemic-euglycemic clamps revealed that obese TPL2KO mice have an improved insulin sensitivity compared with obese WT mice. Hyperinsulinemic-euglycemic.
Cyp8b1−/− mice have improved islet insulin secretion and increased islet insulin content but unchanged β-cell mass. Cyp8b1−/− mice have improved islet.

Cyp8b1−/− mice have improved islet insulin secretion and increased islet insulin content but unchanged β-cell mass. Cyp8b1−/− mice have improved islet.
Effect of metformin on glycemic control, insulin secretion, and insulin sensitivity in T2D. Effect of metformin on glycemic control, insulin secretion,

Effect of metformin on glycemic control, insulin secretion, and insulin sensitivity in T2D. Effect of metformin on glycemic control, insulin secretion,
A–L: Xenin-25 amplifies the effects of GIP on plasma insulin, C-peptide, and glucose levels and ISRs in humans with NGT and IGT but not T2DM. A–L: Xenin-25.

A–L: Xenin-25 amplifies the effects of GIP on plasma insulin, C-peptide, and glucose levels and ISRs in humans with NGT and IGT but not T2DM. A–L: Xenin-25.
NOx ASR (in mmol/day), arginine Ra (in µmol/kg × min), the fraction of arginine flux converted to NOx (%), and the insulin-mediated glucose disposal (M)

NOx ASR (in mmol/day), arginine Ra (in µmol/kg × min), the fraction of arginine flux converted to NOx (%), and the insulin-mediated glucose disposal (M)
A–F: Xenin-25 amplifies the insulin secretory response to GIP in humans with NGT and IGT but not T2DM. A–F: Xenin-25 amplifies the insulin secretory response.

A–F: Xenin-25 amplifies the insulin secretory response to GIP in humans with NGT and IGT but not T2DM. A–F: Xenin-25 amplifies the insulin secretory response.
A and B: Plasma levels of IR-GIP and xenin-25 during GGIs

A and B: Plasma levels of IR-GIP and xenin-25 during GGIs

Similar presentations

Ads by Google